Intra-articular Vancomycin Powder in Knee and Hip Arthroplasty

  • STATUS
    Recruiting
  • End date
    Dec 31, 2027
  • participants needed
    1832
  • sponsor
    Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
Updated on 19 February 2024
total knee replacement
antibiotics
antibiotic therapy
vancomycin
osteonecrosis

Summary

The purpose of this study is to compare infection rates when patients, elected for primary or aseptic revision THA / TKA, have a single intravenous antibiotic dose versus one single intravenous antibiotic dose in combination with intra-articular antibiotics. This is a prospective, randomized clinical survey on selected outcome measurements on 1834 subjects who will be recruited in a period of about 2 years.

Description

Group A: patients receiving single dose of IV cefazolin 10-60 minutes before incision.

Group B: patients receiving a single dose of IV cefazolin 10-60 minutes before incision + a single dose of intra-articular vancomycin powder before articulation (hip or knee) closure.

Details
Condition Infection, Infection
Age 18-100 years
Treatment Arthroplasty
Clinical Study IdentifierNCT04399642
SponsorCentre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
Last Modified on19 February 2024

Eligibility

Yes No Not Sure

Inclusion Criteria

Standard criteria for the implantation of primary total hip or knee replacement
Revision of an aseptic THA or TKA
Adults >18 years of age
Diagnosis of Osteoarthrosis (OA), Osteonecrosis (ON), Arthritis; or aseptic loosening of THA/TKA
Subject is willing to consent to participate in the study
Subject is available for follow-up through at least 2 years
Subject has met acceptable preoperative medical clearance and is free of or treated for medical conditions that would pose excessive operative risk
Subject who are fluent in English and / or French and able to understand their role in the study

Exclusion Criteria

Active, local infection or systemic infection
Participation in any other pharmaceutical, biologic or medical device clinical investigation
Subjects with known allergy to vancomycin
Subjects unable to consent
Patient with skin pathology
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.